Pay in 4 interest-free payments of $5.18 Learn more
Ships within 48 hours · Estimated delivery Aug 24 - Aug 29
doi: 10.1083/jcb.200312135 Centers for Disease Control and Prevention
The presence of severe nonproliferative DR or proliferative DR requires comanagement with retinology and further intervention, including intravitreal injection and/or laser photocoagulation consistent with the clinical standard of care
Descalzo AM, Rossetti L, Grigioni G, Irurueta M, Sancho AM, Carrete J, Pensel NA
Eli Lilly's orforglipron, another oral option, is under FDA review
:max_bytes(150000):strip_icc()/Health-GettyImages-2236560849-a1934f1e4c004a19835cb508d021388b.jpg)
pmid:31905745 22
US$ 24.73
US$ 22.40
US$ 28.44
US$ 25.12
US$ 26.95
US$ 22.33
